Xencor appoints board member
This article was originally published in Scrip
Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, has named Dr Bruce Montgomery a member of its board of directors. Currently, Dr Montgomery serves as CEO of Cardeas Pharma. Prior to Cardeas, he was senior vice-president of Gilead Sciences and was founder and CEO of Corus Pharma, until it was acquired by Gilead in 2006.